In recent years, new therapeutic biological agents targeting the IL-17/IL-23 pathway have proved effective in reducing disease activity, and studies have suggested a preventive role in the structural radiographic progression of spondyloarthritis and psoriatic arthritis [24, 25]. The gene discussed is IL17A; the disease is spondyloarthropathy.